Antigen Presentation Pathway
AACR 2020 Poster
Potent oral ERAP1 inhibitors modify the immunopeptidome in vivo and are novel immunotherapy agents.
Please leave this field empty.
* I consent to giving the above information to Grey Wolf Therapeutics. I am aware my details will be saved for contact and marketing purposes.
Find out more.